T1	intervention 0 25	Ribociclib plus letrozole
T2	control 33 45	chemotherapy
T3	outcome 2861 2885	grade 3-4 adverse events
T4	outcome 2917 2928	neutropenia
T5	cv-bin-abs 2930 2932	31
T6	cv-bin-percent 2934 2937	60%
T7	control-participants 2942 2944	52
T8	outcome 2959 2978	febrile neutropenia
T9	cv-bin-abs 2980 2985	seven
T10	cv-bin-percent 2987 2990	13%
T11	outcome 2997 3003	deaths
T12	outcome 2672 2696	grade 3-4 adverse events
T13	outcome 2741 2752	neutropenia
T14	iv-bin-abs 2754 2756	22
T15	iv-bin-percent 2758 2761	43%
T16	intervention-participants 2766 2768	51
T17	outcome 2783 2831	elevated alanine aminotransferase concentrations
T18	iv-bin-abs 2833 2836	ten
T19	iv-bin-percent 2838 2841	20%
T21	iv-bin-abs 2492 2494	23
T22	intervention-participants 2524 2526	49
T23	cv-bin-abs 2579 2581	24
T24	control-participants 2604 2606	52
T26	iv-bin-abs 2250 2252	44
T27	iv-bin-percent 2254 2257	85%
T28	intervention-participants 2262 2264	52
T29	cv-bin-abs 2307 2309	48
T30	cv-bin-percent 2311 2314	89%
T31	control-participants 2319 2321	54
T33	iv-bin-abs 2401 2406	eight
T34	iv-bin-percent 2408 2411	15%
T35	cv-bin-abs 2417 2420	six
T36	cv-bin-percent 2422 2425	11%
T38	total-participants 2148 2151	106
T40	age 740 749	â‰¥18 years
T41	eligibility 751 794	with stage I-IIIA hormone receptor-positive
T42	location 698 703	Spain
T20	outcome 2232 2248	high ROR disease
T25	outcome 2375 2399	intermediate-ROR disease
T32	outcome 2647 2654	low-ROR
T37	outcome-Measure 1672 1750	proportion of patients with PAM50 low-risk-of-relapse (ROR) disease at surgery
